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■ Abstract  Mutations in the mito-
fusin 2 (MFN2) gene are a major 
cause of primary axonal Charcot-
Marie-Tooth (CMT) neuropathy. 
This study aims at further charac-
terization of cerebral white matter 
alterations observed in patients 
with MFN2 mutations. Molecular 
genetic, magnetic resonance imag-
ing (MRI), magnetic resonance 
spectroscopy (MRS), and diffusion 
tensor imaging (DTI) investiga-
tions were performed in four unre-
lated patients aged 7 to 38 years 
with early onset axonal CMT neu-
ropathy. Three distinct and so far 
undescribed MFN2 mutations were 
detected. Two patients had second-
ary macrocephaly and mild diffuse 
predominantly periventricular 
white matter alterations on MRI. In 
addition, one boy had symmetrical 
T2-hyperintensities in both thal-
ami. Two patients had optic atro-
phy, one of them with normal MRI. 
In three patients proton MRS re-
vealed elevated concentrations of 
total N-acetyl compounds (neuro-
nal marker), total creatine (found 
in all cells) and myo-inositol (as-
trocytic marker) in cerebral white 
and gray matter though with re-
gional variation. These alterations 
were most pronounced in the two 
patients with abnormal MRI. DTI 
of these patients revealed mild re-
ductions of fractional anisotropy 
and mild increase of mean diffu-
sivity in white matter. The present 
findings indicate an enhanced cel-
lular density in cerebral white mat-
ter of MFN2 neuropathy which is 
primarily due to a reactive gliosis 
without axonal damage and possi-
bly accompanied by mild demye-
lination.
■ Key words  hereditary motor 
and sensory neuropathy · Charcot-
Marie-Tooth disease · mitofusin · 
macrocephaly · magnetic 
 resonance spectroscopy
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Introduction
Hereditary motor and sensory neuropathies (HMSN) or 
Charcot-Marie-Tooth syndromes are a group of clini-
cally and genetically heterogeneous disorders of the pe-
ripheral nervous system. Charcot-Marie-Tooth (CMT) 
neuropathies have been divided into predominantly de-
myelinating (CMT1) and predominantly axonal (CMT2) 
forms based on electrophysiological and neuropatho-
logical features. Both conditions are associated with a 
large number of genetic defects. The demyelinating type 
1 is most frequently caused by a 1.4 MB tandem duplica-
tion comprising the PMP22 gene on chromosome 
17p11.2-12 [28]. Mutations of the mitochondrial fusion 
protein mitofusin 2 gene, MFN2, on chromosome 1p36.2 
have been recognized to be associated with CMT type 
2A (CMT2A), an axonal form of Charcot-Marie-Tooth 
neuropathies [35]. MFN2 functions as a mitochondrial 
outer membrane GTPase. It regulates the mitochondrial 
network architecture by fusion of mitochondria and is 
necessary for structural integrity and mobility of mito-
chondria. 
Subsequently, further families presenting clinical and 
electrophysiological features of CMT2A have been iden-
tified with mutations in the MFN2 gene [8, 11, 19, 20]. 
Clinical symptoms in the majority of MFN2 defect pa-
tients reported until now are predominantly confined to 
the peripheral nervous system. The electrophysiological 
characteristics indicate a primary axonal neuropathy. In 
some families with CMT and MFN2 mutations pyrami-
dal signs are present [33]. Furthermore, MFN2 muta-
tions have been found in six families with optic atrophy 
and hereditary motor and sensory neuropathy (HMSN 
VI) [34].
A genotype/phenotype correlation in 29 patients 
with 22 distinct MFN2 mutations revealed two sub-
groups: a larger group with early onset and severe dis-
ease status, and a smaller group with later onset and 
milder clinical course [31]. In a recently reported series 
of 26 patients with CMT2A due to MFN2 mutations, sub-
cortical white matter abnormalities were found by brain 
MRI in eight patients, most of them with late onset dis-
ease [9]. 
Here, we report involvement of the brain in four un-
related patients with early onset axonal CMT disease 
and so far undescribed MFN2 mutations. In three of 
these patients we performed combined magnetic reso-
nance imaging (MRI), magnetic resonance spectroscopy 
(MRS), and diffusion tensor imaging (DTI) investiga-




Four unrelated male patients aged 7 to 38 years were investigated. 
Clinical features are summarized in Table 1. All patients had onset of 
a slowly progressive motor and sensory polyneuropathy in childhood. 
Gait disturbance and foot deformation were present in all; hand func-
tion was mildly to moderately impaired in three patients. Exaggerated 
muscle stretch reflexes were found in patients 1 (until 15 years of age) 
and 3, only the triceps surae reflex was absent. In patient 1, a saccadic 
interruption of horizontal eye movements was noted at 10 years of 
age, which prompted a cranial MRI investigation (see below). Optic 
atrophy was noted in patients 1 and 4. Patient 1 reported visual im-
pairment for the first time at 18 years of age, 15 years after onset of 
motor symptoms. At 17 years, with normal vision, stimulation with an 
alternating checkerboard pattern produced clearly identifiable VEP 
with P2-latencies at the upper limit of normal. One year later, neither 
pattern reversal nor flash stimulation produced an identifiable VEP. 
At this time, visual acuity was 0.5 (right eye) and 0.33 (left eye). Optic 
discs looked normal. Patient 4 had onset of motor symptoms at 3 
years and complained increasing visual difficulties at 5 years of age. 
At 7.5 years, visual acuity was 0.1, optic discs were pale and an afferent 
pupillar defect was present. VEP were not recorded, as the parents 
declined further investigations. Cranial nerves were otherwise nor-
mal in all patients.
 Patients 1 and 2 had a secondary macrocephaly. In patient 1, head 
circumference (HC) grew from the 25th percentile at 5 years to 2 cm 
above the 98th percentile at 18 years of age (Fig. 1a). In patient 2 head 
growth followed the 75th percentile until the age of 11 years, when a 
 Patient 1 2 3 4
 Gender male male male male
 Present age (years) 18 14 38 7
 Affected kinship – father son –
 Onset of symptoms (years) 3 7 7 3
 Loss of walking (years) 10 – – 6
 Hand function impaired impaired normal impaired
 Optic atrophy (onset [years]) +(18) – – +(5)
 Present head circumference > +2SD > +2SD +2SD normal
 MFN2 amino acid change p.R104W IVS5-1G>C p.S378P p.R104W
 MRI abnormal abnormal normal normal
 MRS/DTI abnormal abnormal abnormal n.t.
SD standard deviation; MRS magnetic resonance spectroscopy; DTI diffusion tensor imaging; n.t. not tested
Table 1  Clinical features
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steep increase to a HC of 59.5 cm (1.5 cm > 98th percentile) at 14 years 
of age occurred (Fig. 1b).
Neurophysiological investigations
Details of nerve conduction studies and evoked potentials are given 
in Table 2. In all patients, amplitudes of compound muscle action po-
tentials and sensory nerve action potentials were markedly reduced, 
if recordable at all. Nerve conduction velocities were slightly reduced 
or normal. EEG showed slowing of background activity in patient 4 
and was normal in the other patients.
Histopathological investigations
In patient 1, a sural nerve biopsy at six years of age showed a loss of 
myelinated nerve fibers. There were numerous onion bulb formations 
present indicating repeated episodes of demyelination and remyelin-
ation. Numerous myelin sheaths were too thin in comparison to the 
axon diameter indicative of remyelination. There were no signs of 
acute axonal (Wallerian) degeneration or inflammation present 
(Fig. 2). Electron microscopy confirmed the numerous onion bulbs. 
Non-myelinated axons did not show prominent signs of degeneration 
and there were no pathological inclusions found in Schwann cells.
 In patient 4, a sural nerve biopsy at six years of age revealed reduc-
tion of the larger myelinated fibers. No signs of ongoing atrophy in 
the remaining myelinated fibers were found. Signs of regeneration 




Genomic DNA was extracted from peripheral blood samples by the 
salting-out method. DNA was diluted to a concentration of app. 50 
ng/ml and stored at 4 °C. Primers flanking the exons of the mitofusin2 
(MFN2) gene were created by using the Exon Locator program (http://
exon.swmed.edu/) of the BioSupplyNet. Oligonucleotide sequences 
and PCR conditions are available on request. The complete coding 
region of the exons and flanking intronic sequences were amplified. 
The purified PCR products were sequenced on both strands using the 
BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) on an 
ABI 3730 automated capillary sequencer (Applied Biosystems). The 
resulting sequences were compared to the reference sequences 
(MFN2, genomic contig: NT_021937, cDNA: NM_014874) given in the 
NCBI-database (http://www.ncbi.nlm.nih.gov) and sequence varia-
tions were documented. Sequence traces were evaluated using the 
DNAStar software package. 
Magnetic resonance investigations
In patient 1, MRI investigations were performed at 11 and 17 years of 
age at 1.5 T (Philips NT Gyrovision). Combined MRI and MR spec-
troscopy studies were carried out at 3 T (Siemens Magnetom Trio, 
Erlangen, Germany) using the standard eight channel phased-array 
headcoil at 17 years of age in patient 1, at 14 years in patient 2, and at 
38 years in patient 3. Written informed consent was obtained from 
patients and, in patients 1 and 2, from their parents. The study was 
approved by the Ethics Committee of the University Göttingen. In 
patient 4, MRI was carried out at 1.5 T, additional MRS or DTI inves-
tigations were not performed.
 Fully relaxed short-echo time proton MR spectra were acquired 
by means of a single-voxel stimulated echo acquisition mode (STEAM) 
localization sequence (TR/TE/TM = 6000/20/10 ms, 64 accumula-
tions) as described previously [13, 22]. Volumes of interest (VOI) were 
selected from T1-weighted (3D MP-RAGE) and T2-weighted (3D TSE 
with variable flip angle) images and were located in affected frontal 
and parieto-occipital white matter (WM, 4.1 ml) and paramedian pa-
rietal gray matter (GM, 12.5 ml). 
 Spectral evaluation and quantification of absolute metabolite 
concentrations were accomplished with the use of LCModel [26]. The 
approach represents a user-independent fitting routine based on a 
library of calibrated model spectra of individual compounds and 
therefore avoids bias due to manual post-processing. Metabolite con-
centrations are expressed in mM, i.e. mmol per liter VOI, without cor-
rections for CSF contributions and residual T2 relaxation effects. 
Further details of MRS data acquisition and spectral evaluation have 
been described elsewhere [12]. A total of ten healthy subjects were 
examined and grouped according to their age to provide age-matched 
control values for each patient. Values deviating from the mean nor-
mal concentration by 2 SD or more were regarded as abnormal.
 Major detectable metabolites include the neuroaxonal markers 
Fig. 1  Head growth of patient 1 (a) and patient 2 
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[4] N-acetylaspartate and N-acetylaspartylglutamate (tNAA), cre-
atine and phosphocreatine (tCr) as ubiquitous compounds linked to 
energy metabolism [30], choline-containing compounds (Cho) in-
volved in membrane turnover [15], the glial (astrocytic) marker myo-
inositol (Ins) [5], and lactate (Lac) as the intermediate product of 
nonoxidative glucose consumption. 
 Diffusion tensor imaging (DTI) was performed using a partial 
Fourier single-shot STEAM sequence [27]. In an axial orientation 38 
consecutive sections of 2.2 mm thickness were acquired (TR 16.2 s, TE 
50 ms, flip angle 10°, 2.2 × 2.2 mm² in-plane resolution, 3–4 averages), 
comprising a non-diffusion-weighted image and 24 images with dif-
fusion-weighting in two sets of 12 directions with opposite sign (ico-
sahedron scheme), at a b-value of 1000 s/mm². Maps of the mean dif-
fusivity (MD) and the fractional anisotropy (FA) were calculated from 
the diffusion tensor and co-registered with the anatomical images 
using FSL 3.2 (FMRIB Software Library, Oxford). In a region-of-inter-
est analysis MD- and FA-values were determined for the VOIs used for 
localized MRS of white matter as well as for the centrum semiovale. 
These values were compared to age-matched control values obtained 
from the ten healthy subjects.
Fig. 2  Sural nerve biopsy of patient 1 at 4 years of age, toluidine blue stain, x100 
magnification, shows a loss of myelinated nerve fibers with onion bulb formations, 
thin myelin sheaths in relation to axon diameter, and absence of any signs of 
acute axonal degeneration or inflammation. Thinly myelinated axons (small black 
arrows), onion bulb (big blank arrow), and regenerating clusters (big black arrows) 
are labeled
Table 2  Results of neurophysiological investigations in the four patients 
A Motor nerve conduction studies
















 1 17  0 0  0 0  0  0  0  0
 2 14 44 0.6 35 0.2 59 14 63 12
 3 38  0 0  0 0 49 12 48  5
 4  7  0 0  0 0 n.t. n.t. n.t. n.t.
n.t. not tested
B Sensory nerve conduction studies








 1 17  0  0  0  0
 2 14 46 14 60 30
 3 38  0  0 36  2
 4  7  0  0 n.t. n.t.
n.t. not tested
C Evoked potentials
 Patient Age BAEP Median SSEP Tibial SSEP VEP 
P100 latencies, left/right eye (ms)*
 1 17
18
N no SSEP identifiable no SSEP identifiable 112/110
no VEP identifiable
 2 14 N N P1-latencies prolonged 99/100
 3 38 n.t. N no SSEP identifiable 98/100
CV conduction velocity; N normal; n.t. not tested; * Pattern reversal stimulation, P100 latency: mean 101 ± 3.5 ms, normal ≤ 111.5 ms




In the mitofusin 2 gene of patient 1 and 4, who are not 
related, we detected the heterozygous variation cytosine 
to thymine (c.310 C>T) in the second coding exon. The 
consequence is a change of arginine at position 104 to 
tryptophan (p.R104W). This variation was not detected 
in the patient’s healthy parents and thus occurred de 
novo for patient 1. The parents of patient 4 were not 
available for genetic analysis. 
In patient 2 the mutation IVS5-1G>C was identified 
heterozygous. This variation affects the canonic splice 
acceptor site. The same mutation was found in his mildly 
affected father, whereas his healthy mother carried the G 
nucleotide in both alleles required for splicing.
In patient 3 the heterozygous mutation thymine to 
cytosine (c.1132 T>C) in the ninth coding exon was 
found. The consequence is a change of the amino acid 
serine at position 378 to proline (p.S378P). This is also a 
de novo mutation, since the healthy parents carry the 
wildtype allele. 
All three identified patient mutations were not found 
in 100 healthy controls. Furthermore, these mutations 
have not been described previously.
■ Magnetic resonance imaging
In patient 1, MRI at 11 years revealed a mild diffuse hy-
perintensity of supratentorial white matter in T2- and 
FLAIR-weighted images. These signal alterations were 
diffuse but more prominent periventricularly in the pa-
rieto-occipital regions. A follow-up investigation at 17 
years showed these hyperintensities unchanged (Fig. 3). 
In patient 2 at 14 years of age, MRI showed mild signal 
alterations of predominantly periventricular parieto-
occipital white matter similar to the pattern in patient 1. 
In addition, symmetrical T2-hyperintensities were visi-
ble in lateral parts of both thalami (Fig. 3e). MRI was 
normal in patient 3 at 38 years and in patient 4 at 7 years 
of age.
■ Magnetic resonance spectroscopy
MR spectra showed no gross abnormalities in any of the 
investigated patients (Fig. 4). However, absolute quanti-
fication of metabolite concentrations (Table 3) revealed 
elevated concentrations of tNAA and tCr in all three pa-
tients though with regional variation. Of the two patients 
(1 and 2) with mild, predominantly parieto-occipital 
leukoencephalopathy on MRI, only patient 1 had mod-
erate elevations of tNAA (+20 %), tCr (+28 %), and 
marked increase of Ins (+67 %) in the affected region as 
well as elevated Ins (+30 %) in frontal WM. In both pa-
Fig. 3  T2-weighted (a, b) and FLAIR-
weighted (b, d) MRI (1.5 T) of patient 
1 at 11 (a, b) and 17 years (c, d) of age 
shows non-progressive mild diffuse 
hyperintensity of supratentorial white 
matter predominantly in the periven-
tricular regions. E T2-weighted axial MRI 
of patient 2 at 14 years of age showing 
stripes of hyperintensity in the lateral 
parts of both thalami
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tients moderate elevations of tNAA (+26 % and +23 %) 
and tCr (+26 % and +24 %) were found in parietal GM. 
In patient 3 with normal MRI, MRS of WM revealed mild 
increase of tNAA in frontal (+16 %) and parieto-occipi-
tal (+10 %) regions together with marked increase of tCr 
(+57 %) in the frontal area. This was accompanied by 
clear elevation of Ins in both frontal (+52 %) and pari-
eto-occipital (+36 %) regions. A sole increase of Cho 
(+27 %) was detected in frontal WM of patient 3, all 
other Cho levels were within the normal range. Remark-
ably, concentrations of lactate were within the normal 
range in all regions in all patients.
■ Diffusion tensor imaging
DTI revealed only mild deviations from age-matched 
controls, as summarized in Table 4. We found mildly de-
creased FA (> 2 SD) in centrum semiovale of both pa-
tients 1 and 2 with abnormal T2-hyperintensity of peri-
ventricular white matter. Deviations of FA in frontal and 
parieto-occipital white matter of these two patients were 
inconsistent, with a tendency to reduction. Fig. 5 depicts 
the FA map of patient 1 in comparison to an age-matched 
control. MD was increased in frontal white matter of 
both patients and in centrum semiovale of one of them. 
In patient 3, who had normal MRI, DTI revealed a mild 
elevation of FA in frontal white matter but otherwise no 
significant deviations from controls for FA and MD. 
Discussion
Our study provides evidence for an involvement of cere-
bral white matter or optic nerves or both in four patients 
with CMT2 due to MFN2 mutations. Novel observations 
reported here include (i) the appearance of secondary 
macrocephaly in two patients (1 and 2) in their second 
decade, (ii) clear histopathological signs of demyelin-
ation in addition to features of axonal neuropathy in the 
sural nerve biopsy of one patient (1), (iii) involvement of 
thalami in one patient (2), (iv) metabolic and micro-
4 3 2 1





Fig. 4  Proton MRS (STEAM, TR/TE/TM = 6000/20/10 ms) of right parieto-occipital 
white matter of patient 1 at 17 years of age 
Table 3  Cerebral metabolite concentrations (mM) in white and gray matter and 
age-matched controls (mean ± SD) 
 Patient Region tNAA tCr Cho Ins
 1 WM LF 6.2 4.6 1.7 3.5
 2 WM LF 6 3.9 1.7 2.9
 Control (n = 6, 11–21 yrs) 6.3 ± 0.9 4.2 ± 0.7 1.6 ± 0.6 2.7 ± 0.6
 1 WM RPO 9.1* 5.5* 1.6 4.5*
 2 WM RPO 7.5 4.3 1.5 2.9
 Control (n = 6, 11–21 yrs) 7.6 ± 0.6 4.3 ± 0.6 1.6 ± 0.5 2.7 ± 0.6
 1 GM PMP 8.3* 6.1* 1.2 4.2
 2 GM PMP 8.1 6.2* 1.3 3.7
 Control (n = 6, 11–21 yrs) 6.6 ± 0.8 4.9 ± 0.6 1.0 ± 0.3 3.7 ± 1.1
 3 WM LF 7.1* 5.8* 1.9* 4.4
 Control (n = 3, 35–45 yrs) 6.1 ± 0.5 3.7 ± 0.5 1.5 ± 0.2 2.9 ± 0.8
 3 WM RPO 8.0* 4.3 1.6 3.8*
 Control (n = 3, 35–45 yrs) 7.3 ± 0.1 4.1 ± 0.6 1.5 ± 0.3 2.8 ± 0.4
 3 GM PMP 6.8 5.1 1.1 3.2
 Control (n = 3, 35–45 yrs) 7.0 ± 0.7 5.0 ± 0.1 1.0 ± 0.1 3.2 ± 0.1
WM white matter; LF left frontal; RPO right parieto-occipital; GM gray matter; PMP 
paramedian parietal; * ≥ 2 SD from control
Table 4  Fractional anisotropy (FA) and mean diffusivity (MD) in WM of our 
patients and age-matched controls (mean ± SD)
 Patient Region FA MD
 1 WM LF 0.23* 0.79* 
 2 WM LF 0.28* 0.72*
 Control (n = 6, 12–21 yrs) 0.26 ± 0.01 0.69 ± 0.01
 1 WM RPO 0.3 0.76
 2 WM RPO 0.27 0.73
 Control (n = 6, 12–21 yrs) 0.33 ± 0.04 0.74 ± 0.02
 1 WM R CS 0.33* 0.72*
 2 WM R CS 0.32* 0.69
 Control (n = 6, 12–21 yrs) 0.36 ± 0.01 0.67 ± 0.02
 3 WM LF 0.28* 0.7 
 Control (n = 3, 35–45 yrs) 0.25 ± 0.01 0.69 ± 0.01
 3 WM RPO 0.29 0.7
 Control (n = 3, 35–45 yrs) 0.3 ± 0.03 0.74 ± 0.03
 3 WM R CS 0.27 0.66
 Control (n = 3, 35–45 yrs) 0.3 ± 0.02 0.66 ± 0.02
WM white matter; LF left frontal; RPO right parieto-occipital; R CS right centrum 
semiovale; * ≥ 2 SD from control
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structural alterations detected by multiparametric MR 
investigations of cerebral white matter indicating en-
hanced neuroaxonal density, astrocytosis, and possibly 
mild demyelination in three patients (1–3), and (v) a 
splice site mutation in one patient (2) pointing to haplo-
insufficiency in MFN2 associated CMT.
The secondary macrocephaly in patients 1 and 2 
(Fig. 1) constitutes a clinical feature of uncertain signifi-
cance. This course of head growth is not typical for a 
familial macrocephaly, and, in patient 1, it is not likely 
that this macrocephaly is due to the large HCs of both 
unaffected parents. At present, we can only presume that 
the relationship between MFN2 mutation and secondary 
macrocephaly in both boys is more likely to be cause and 
effect rather than mere coincidence. Remarkably, HC of 
patient 3 is also in the 98th percentile range.
Reports on sural nerve biopsies in patients with 
MFN2 mutations are rare, and the histopathological 
findings are not uniform. The biopsies in the two pa-
tients presented here show features of axonal degenera-
tion and additionally, in patient 1, clear signs of repeated 
demyelination and remyelination with the formation of 
onion bulbs. These findings are compatible with the de-
scription of sural nerve pathology in a patient with late 
disease onset [9]. In this patient the authors show my-
elinated fibers being well preserved similar to our pa-
tient 1. This is in contrast to the pathological features of 
a patient with early onset disease [9] and another patient 
described by Verhoeven et al. [31]. In these two cases a 
severe loss of myelinated fibers was observed with no 
evidence of regeneration or remyelination. Thus, the 
spectrum of sural nerve pathology in patients with 
MFN2 mutations may be broader than expected and 
may also include a remyelinating phenotype as described 
in the present patient beside the axonal degeneration 
reported previously. 
Fig. 5  Axial maps of the fractional anisotropy 
(thresholded at FA = 0.17) overlaid on T1-weighted 
MRI of patient 1 (a, b) and a healthy, age-matched 
control (c, d)
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While MRI showed mild diffuse signal hyperintensi-
ties in T2- and FLAIR-weighted images in the two pa-
tients (1 and 2) with secondary macrocephaly and mod-
erate to severe clinical course of peripheral neuropathy, 
MRI was normal in the older patient (3) with milder 
clinical features and in the 7-year-old boy (4) with signs 
of optic atrophy. In three patients, MRS revealed in-
creases of tNAA, tCr and Ins with regional variation and 
to variable degree. DTI showed mild abnormalities in 
cerebral WM comprising decreased FA and elevated MD 
in the two patients with abnormal MRI.
We found no clear correlation between extent of T2-
signal changes on MRI and metabolic alterations de-
tected by MRS. Clearly, however, MRS yielded no evi-
dence for axonal loss in cerebral white matter that 
parallels the histological findings in the peripheral 
nerve. This is in line with the lack of clinical and neuro-
physiological features indicating marked CNS dysfunc-
tion. The only pyramidal tract signs that were present 
during the first years of the disease were exaggerated 
muscle stretch reflexes. Saccadic interruption of hori-
zontal eye movements constituted the mild abnormality 
that prompted the MRI investigation of the brain in pa-
tient 1. Clinical examination, brainstem evoked poten-
tials, and MRI provided no evidence for any brainstem 
or cerebellar abnormalities in this patient. One might 
speculate that disordered mitochondrial fusion in pa-
tients with MFN2 mutations could result in a change in 
NAA synthesis in neuronal mitochondria, but we have 
no evidence to support this hypothesis. The occurrence 
of secondary macrocephaly in patients 1 and 2 could be 
due to cerebral edema. However, this would result in 
more prominent T2-hyperintensity on brain MRI and 
reduced concentrations of major cerebral metabolites in 
MRS, as seen in laminin alpha2 chain deficiency [6]. On 
the other hand, macrocephaly may suggest an increase 
of volume of cerebral tissue. Astrocytic proliferation, as 
seen in Alexander disease, may result in secondary mac-
rocephaly. Assuming changes in metabolite concentra-
tions to reflect changes in cellular tissue composition 
rather than intracellular metabolism, the observation of 
increased tNAA (neuronal origin), tCr (all cells) and Ins 
(astrocytic origin) in our patients is best understood as 
the simultaneous presence of a pronounced astrocytic 
proliferation and enhanced neuroaxonal density.
MRI abnormalities and metabolic changes detected 
by MRS are complemented by only mild alterations of 
water diffusivity demonstrated by DTI. In general, white 
matter diffusion anisotropy reflects the integrity of both 
axonal membranes and myelin sheaths. Without any in-
dication of axonal damage in proton MRS, the DTI find-
ings hint to a mild demyelination which – together with 
the MRS alterations – seems to be accompanied by a 
more dense packing of axons (per image voxel) as well 
as a reactive gliosis. Thus, the present study suggests 
possible differences in the pathogenetic mechanisms of 
axonal CMT disease due to MFN2 mutations in periph-
eral and central nervous system. 
Reports on involvement of cerebral white matter in 
CMT disease are rare. Preserved or increased muscle 
stretch reflexes and, in some cases, extensor plantar re-
sponses and increased muscle tone are features of HMSN 
type V according to Dyck [14, 18]. MRI investigations of 
the brain have not been reported in these studies. 
Disseminated lesions of subcortical white matter 
demonstrated by MRI of the brain have been described 
in single patients with hereditary neuropathy with lia-
bility to pressure palsies [1, 10]. In CMT disease due to 
connexin 32 (Cx32, GJB1) mutations multifocal and in 
some cases transient and recurrent white matter lesions 
have been demonstrated by MRI of the brain [17, 21, 23]. 
In two male patients with X-linked CMT due to Cx32 
mutations transient ataxia, dysarthria and weakness 
were associated with transient symmetrical white mat-
ter abnormalities on MRI. Additional proton MRS in one 
patient using metabolite ratios revealed a small decrease 
of tNAA/tCr ratio and elevated Cho/tCr ratios [24]. Fur-
ther characterization using MR methods or histopatho-
logical studies of these white matter alterations are not 
available. 
Neurological features of patients with MFN2 muta-
tions reported previously are confined to the peripheral 
nervous system in most cases. A MFN2 mutation has 
been detected in a family with pyramidal signs [33] 
comprising extensor plantar responses, mild increase in 
tone, and preserved or increased reflexes but no spastic 
gait. Brain MRI was available from one member of this 
family and was normal [32]. MFN2 mutations were 
found in six families with HMSN VI, characterized by 
axonal neuropathy and optic atrophy [34]. Most of these 
patients had subacute onset of optic atrophy and subse-
quent slow recovery of visual acuity. No data regarding 
head circumferences are available. MRI or contrast-en-
hanced cranial CT scans were performed in at least one 
affected individual in five of the six families. These in-
vestigations were unremarkable in all but one patient, 
who had increased T2 signal in both cerebellar pedun-
cles. Periventricular changes were not present [34].
More recently, a study of 26 patients from 15 families 
with CMT2A due to MFN2 mutations confirmed the de-
lineation of an early onset group with severe clinical and 
electrophysiological features and a late onset group with 
milder clinical course [9]. In eight of these patients 
(seven in the late onset and only one in the early onset 
group), brain MRI disclosed abnormal, unspecific T2-
hyperintensities in subcortical and periventricular white 
matter. Data on head circumferences were not given. 
A missense mutation p.R104W was found in our un-
related patients 1 and 4. An exchange from arginine to 
tryptophan replaces an alkaline with a neutral amino 
acid residue. The arginine at position 104 is located 
within the GTPase domain of the MFN2 protein and is 
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evolutionary highly conserved from the worm Chae-
norhapditis elegans over the fruitfly Drosophila melano-
gaster up to homo sapiens. The severity of the clinical 
course of the neuropathy in both patients may be ex-
plained by a loss of function within the GTPase domain 
in MFN2. In both patients weakness started as early as 3 
years of age and progressed rapidly, resulting in loss of 
walking at 10 years in patient 1 and at six years in patient 
4. Both developed optic atrophy, patient 4 earlier than 
patient 1. White matter changes on MRI were first de-
tected in patient 1 at 11 years, and macrocephaly ap-
peared only at 16 years. Follow-up investigations will 
reveal whether these features will appear in patient 4, 
now aged seven years, later in the course. Histopatho-
logical investigation of sural nerve biopsies performed 
in both patients at the age of six years revealed features 
of axonal neuropathy in both boys and additional clear 
signs of demyelination in patient 1.
In patient 3 with a milder clinical course we detected 
a missense mutation p.S378P. An exchange from serine 
to proline replaces a hydrophilic with a slightly polar 
amino acid residue. Proline is common in peptide bend-
ing or turns of the amino acid chain. The serine at posi-
tion 378 of the MFN2 protein is conserved in mouse and 
rat and also in other GTPases like the transmembrane 
GTPase Fzo [16]. In D. melanogaster the serine at posi-
tion 378 is replaced by asparagine, an uncharged polar 
amino acid, whereas the corresponding C. elegans pro-
tein also exhibits serine at the comparable position. 
Thus, the evolutionary conservation is not as strict as for 
the p.R104W variation in patients 1 and 4. On the other 
hand the serine at position 378 is located in a conserved 
interdomain region. The amino acid position as well as 
the nature of the mutation in patient 3 point to less se-
vere effects on the cellular level. 
The mutation IVS5-1G>C detected in patient 2 elim-
inates a canonic splice signal. Thus it can be predicted 
that exon 5 will be skipped and exon 6 is fused directly 
to exon 4. Under this assumption a frame shift results 
with a preliminary termination of translation at a tga 
codon in position 106. Hence the vast majority of the 757 
amino acids of the wildtype protein is lost including the 
GTPase domain. This remaining protein fragment may 
be immediately degraded by proteolysis. Alternatively, 
one may assume a nonsense-mediated mRNA decay as a 
possible pathway. Thus, this mutation mimics a partial 
deletion or even a null allele of MFN2 reducing the effec-
tive dosage. In this context the associated phenotype 
corresponds to a haploinsufficiency due to a loss-of-
function mutation. 
Size and morphological arrangement of mitochon-
dria are supposed to be the result of a dynamic balance 
between mitofusin-dependent mitochondrial fusion 
and dynamin-related protein dependent mitochondrial 
fission [29]. This balance varies with both cellular dif-
ferentiation and human disease. MFN2 is a mitochon-
drial membrane protein that (i) mediates the fusion of 
mitochondria, and (ii) regulates mitochondrial mem-
brane potential, fuel oxidation, and the OXPHOS system 
[25]. MFN2 is ubiquitously expressed [2] and mRNA 
transcripts have been detected in spinal cord and pe-
ripheral nerve [35]. It has been proposed that the meta-
bolic accelerator and the mitochondrial fusion roles of 
MFN2 are distinct functions and that this may explain 
the sensitivity of the neuronal cell with its high energy 
demands to a partial MFN2 loss-of-function [25]. MFN2-
deficient mice showed a reduced mitochondrial mobil-
ity [7], and a recent study demonstrated that disease-as-
sociated MFN2 mutant proteins induced impaired 
axonal mitochondrial transport in cultured dorsal root 
ganglion neurons [3]. Mobility and transport of mito-
chondria are crucial for the viability of long axons in 
both peripheral nerves and central tracts. However, the 
detailed mechanisms of MFN2 deficiency in CMT are 
poorly understood. Additional observations will eluci-
date whether secondary macrocephaly is a clinical hall-
mark of MFN2 neuropathy and further studies have to 
explain why MFN2 mutations result in primary axonal 
damage in the peripheral nerve versus astrocytic prolif-
eration in cerebral white matter.
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